Paradigm, a New York-based healthcare technology company, raised $203M in Series A funding.
The round was led by ARCH Venture Partners and General Catalyst, with participation from F-Prime Capital, GV, LUX Capital, Mubadala Capital, Magnetic Ventures, and American Cancer Society’s BrightEdge fund.
The company will use the proceeds of this financing to expand its existing platform and scale its partnerships with healthcare systems and life sciences companies. Paradigm has also acquired Deep Lens, a company providing technology-enabled clinical trial patient recruitment in oncology leveraging electronic medical records and genomics data.
Led by CEO Kent Thoelke, Paradigm is a healthcare technology company focused on improving access to clinical research for patients. Its clinical trial platform enables equitable access for all patients by enhancing trial efficiency and reducing the barriers to participation for healthcare providers.
The system aims to reduce the operational burden on physicians and healthcare provider organizations and improve access for patients.
